capsaicin

(redirected from Qutenza)
Also found in: Dictionary, Thesaurus, Medical.

capsaicin

[kap′sā·ə·sən]
(organic chemistry)
C18H27O3N A toxic material extracted from capsicum.
Mentioned in ?
References in periodicals archive ?
Anthony DiTonno, CEO of NeurogesX, commented, "Securing an agreement with Astellas for the commercialization of Qutenza in Europe and additional territories is a significant milestone achievement for NeurogesX.
Under the Distribution, Marketing and License Agreement, NeurogesX will receive two upfront payments from Astellas, EUR 30 million (approximately $42 million) for Qutenza commercialization rights and EUR 5 million (approximately $7 million) for a co-development and commercialization option of NGX-1998.
NeurogesX is eligible for additional sales-based milestone payments and additional option payments related to the liquid formulation totaling approximately EUR 70 million ($97 million) and royalties based on a double-digit percentage of net sales for Qutenza.
Astellas has committed investment for additional studies to support the marketing and promotion of Qutenza and to fulfill post-marketing commitments outlined in the European Commission's approval.
Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN).
label for Qutenza for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN), also known as HIV-associated neuropathy or HIV-distal sensory polyneuropathy.
Examples of such statements include but are not limited to: statements regarding expected uses of the proceeds from the debt financing with Hercules, as well as the expected benefits resulting from such proceeds; NeurogesX' ability to fund its operations, based on existing cash as well as the proceeds from the Hercules debt financing and the July 2011 private placement equity financing, into 2013; the potential pursuit of partnering activities for NGX-1998; expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza; and the potential benefits of Qutenza and NGX-1998.
Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: delays in obtaining clinical study data for NGX-1998, difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submission of the sNDA for Qutenza; and potential patent invalidation prior to expiration or other potential adjustment of the patent term.
Examples of such statements include but are not limited to: statements regarding expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza; the potential benefits of Qutenza and NGX-1998; expected proceeds and closing of the private placement; and the registration of any shares issued directly or indirectly in connection with the private placement.
Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: delays in obtaining clinical study data for NGX1998, difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submission of the sNDA for Qutenza; and potential patent invalidation prior to expiration or other potential adjustment of the patent term.